Ken Griffin Xenon Pharmaceuticals Inc. Put Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	SELL	$36.12 - $43.96 $130,031 - $158,256	-3,600 Reduced 50.0%	3,600 $141,000
Q2 2024 Aug 14, 2024	SELL	$36.25 - $43.75 $119,625 - $144,375	-3,300 Reduced 31.43%	7,200 $280,000
Q1 2024 May 15, 2024	SELL	$42.66 - $50.04 $6.04 Million - $7.09 Million	-141,600 Reduced 93.1%	10,500 $452,000
Q4 2023 Feb 14, 2024	BUY	$28.7 - $46.46 $3.77 Million - $6.1 Million	131,200 Added 627.75%	152,100 $7.01 Million
Q3 2023 Nov 14, 2023	BUY	$34.16 - $39.73 $570,472 - $663,491	16,700 Added 397.62%	20,900 $713,000
Q2 2023 Aug 14, 2023	SELL	$34.84 - $43.54 $114,972 - $143,682	-3,300 Reduced 44.0%	4,200 $161,000
Q1 2023 May 15, 2023	SELL	$33.46 - $40.35 $374,752 - $451,920	-11,200 Reduced 59.89%	7,500 $268,000
Q4 2022 Feb 14, 2023	SELL	$33.06 - $39.43 $211,584 - $252,352	-6,400 Reduced 25.5%	18,700 $737,000
Q3 2022 Nov 14, 2022	BUY	$30.79 - $39.82 $344,848 - $445,984	11,200 Added 80.58%	25,100 $906,000

212

70.2M

88.3K

28.8K

Ticker XENE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,263,500
Market Cap $2.39B
Description
Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopath...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.